Table 3.

Multivariate analysis for the association between clinical characteristics and survival in all and landmark groups with metastatic colon cancer received mFOLFOX6 as first-line treatment

	All patients				Landmark patients
	PFS		OS		PFS		OS
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR(95%CI)	P value
KPS
80 vs. 90*	0.963 (0.927–1.000)	0.052	1.039 (1.009–1.146)	0.041	1.077 (1.004–1.122)	0.013	1.016 (1.005–1.045)	0.046
Liver metastasis
Presence vs. absence*	1.746 (1.127–2.706)	0.013	1.527 (0.963–2.422)	0.072	1.480 (0.967–2.265)	0.071	1.504 (0.911–2.482)	0.111
Pathological differentiation
Well-moderate vs. poor*	1.006 (0.742–1.364)	0.096	0.658 (0.472–0.918)	0.014	1.050 (0.757–1.456)	0.770	0.626 (0.434–0.904)	0.012
Timing of CIN
Early-onset vs. Absence*	0.501 (0.152–0.854)	0.032	0.378 (0.113–0.726)	0.021	0.698 (0.161–0.937)	0.042	0.471 (0.109–0.834)	0.023
Late-onset vs. Absence*	0.656 (0.275–0.932)	0.046	0.762 (0.219–0.865)	0.042	0.776 (0.303–0.947)	0.032	0.828 (0.230–0.957)	0.041
Severity of CIN
Mild CIN vs. Absence*	0.580 (0.166–2.033)	0.395	0.509 (0.145–1.787)	0.292	0.437 (0.095–2.015)	0.288	0.433 (0.095–1.976)	0.280
Severe CIN vs. Absence*	0.525 (0.164–1.681)	0.278	0.606 (0.185–1.982)	0.407	0.383 (0.090–1.619)	0.192	0.487 (0.115–2.064)	0.329

^*The later after vs. was the reference. Hazard ratios of survival with 95% CI were estimated with Cox’s proportional hazards model

Adjusted for: KPS; Pathological differentiation; Liver metastasis; Severity of CIN; Timing of CIN